Ruben Mesa, MD: Momelotinib Non-Inferior to Ruxolitinib in Myelofibrosis

On location

Dr. Mesa reviews data from the SIMPLIFY 1 trial, which compared the novel JAK1/2 inhibitor momelotinib with ruxolintinib in patients with JAK inhibitor–naïve MF, in which momelotinib was non-inferior to ruxolitinib in splenic volume reduction, but failed to improve disease symptoms.